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ABSTRACT 
Recently, nanoscale stimuli-responsive devices have received much attention thanks to their 
potential to limit the cytotoxic effect of the therapeutic treatment at the diseased tissue. 
Among different physical triggers, large alternating magnetic fields enable the conversion of 
magnetic energy into heat by using magnetic nanoparticles that generate localized 
hyperthermia, named Magneto Fluid Hyperthermia (MFH). This methodology can be 
exploited for cancer therapy or/and thermally activated drug release. The small size iron oxide 
nanoparticles (Fe-NPs), such as SPIO (small iron oxide particles) and USPIO (ultra-small iron 
oxide particles), currently used for this application have many limitations due to their 1)high 
intratumor concentration needed due to the low heating power 2)short particle blood-half-life, 
3)non-specific distribution, 4)low internalization efficiency. For these reasons many efforts 
are necessary to make magneto fluid particle hyperthermia (MFH) a competitive tumor 
therapy for clinical applications. New iron oxide nanoparticles, coated with oleate, with a 
diameter of 5-18 nm, have been prepared by co-precipitation and incorporated into PLGA-
NPs (PLGA=Poly(lactic-co-glycolic acid) in order to improve their biocompatibility and “in 
vivo” stability. Moreover, PLGA-NPs have been loaded with both NPs-Fe and antitumor 
drugs (Paclitaxel, PTX), an anticancer hydrophobic drug used in the treatment of ovarian and 
breast cancer, to perform MFH triggered drug release. The PTX and Fe-NPs loaded 
nanoparticles may be considered as an effective anticancer drug delivery system for Imaging-
guided hyperthermic treatment of tumors. 
  
 
 
 
INTRODUCTION  
   Biological applications of nanotechnology have become the central focus in cancer 
treatment and research due to their potential in detecting cancer at the cellular scale (early 
stage), entering the region, and destroying the cells before they start to proliferate to form a 
tumor mass [1].  
The use of hyperthermia treatment as an adjuvant for cancer therapies has been known since 
3000 BC when some patients were treated by using hot sand baths and saunas [2]. Between 
the range of 40°C and 43°C, the majority of cancer cells tend to die by activation of several 
biochemical processes, firstly with enhanced production of heat shock protein (hsp), while 
healthy cell survive [3]. 
Hyperthermia may be induced locally, regionally or in the whole body for the treatment of 
tumor [4]. Local hyperthermia induces the least severe side effects and it is performed by 
wide different approach, including radiofrequency ablation, focused ultrasound, laser ablation 
and, recently, Magnetic Fluid Hyperthermia [5].  
Magnetic fluid hyperthermia (MFH) is one of clinical nanotherapies, recently approved in 
Europe for treatment of glioblastoma and used in some clinical trials by MagForce (Berlin, 
Germany) to treat prostate and pancreatic cancer [6]. It relies on the use of magnetic 
nanoparticles (MNPs) as heat generators to induce localised cell death by the application of 
external alternating magnetic field (AMF) [7]. Different mechanisms are responsible for the 
thermal energy generated by magnetic nanoparticles after application of an AMF. They are 
strongly related to the magnetic properties of magnetic nanoparticles (i.e. the overall 
magnetization (Ms), and the effective anisotropy constant (Keff)) that are strictly dependent on 
their size, shape and composition [8]. In particular, the mechanism of energy dissipation can 
either be through Néel relaxation, the rapid internal re-orientation of particle’s magnetic 
moment with the applied field, or Brownian relaxation, frictional heating caused by physical 
rotation of magnetic particles [9]. The effective relaxation time (τ) of the magnetic particles is 
defined, in following equation (1), as 
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where τN and τB are the Néel and Brownian magnetic relaxation times, respectively. The 
shorter relaxation time determines the dominant relaxation mechanism. τN and τB magnetic 
relaxation times of a particle are given by the following equations (2) and (3)[9]: 
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where τ0 = 10-9 s, K the anisotropy constant, VM the volume of particle, k the Boltzmann 
constant, T the temperature, η the viscosity and VH the hydrodynamic particle volume. 
The relative contribution arising from Néel and Brown relaxation processes depend on the 
particle size, shape and chemical characteristics. The Néel time has an exponential 
dependence on magnetic anisotropy and particle volume, whereas the Brownian correlation 
time varies linearly with particle volume and solvent viscosity [10]. Furthermore, theoretical 
and experimental results strongly suggest that highly efficient intracellular hyperthermia 
modality can be achieved by exploiting the Néel rather than the Brown relaxation. 
MNPs are single or multiple inorganic crystal of a magnetic material that offer some attractive 
possibilities in biomedical applications, such as magnetic separation, drug delivery, 
hyperthermia treatments and Magnetic Resonance Imaging (MRI) contrast enhancement [4]. 
For most biomedical application the MNPs are made from ferromagnetic iron oxide, such as 
magnetite (Fe3O4) and magnemite (γ-Fe2O3) as they precisely respond to external magnetic 
fields by mechanical motion or dissipation of thermal energy through relaxation losses [11]. 
The small sized iron oxide nanoparticles (Fe-NPs), such as SPIO and USPIO, clinically 
approved for MRI and hyperthermia application have many limitations due to their high 
intratumor concentration needed as a consequence of the low heating power and their non-
specific distribution [12]. For these reasons many efforts are necessary to make magneto fluid 
particle hyperthermia (MFH) a competitive tumor therapy for clinical applications. Moreover, 
it is crucial for the development of MFH to rely on analytical methods able to characterize 
new magnetic nanoparticles and to predict their heating capacity in physiological conditions. 
In this study, the MFH properties of newly prepared iron oxide nanoparticles (MNPs), coated 
with oleate moieties and prepared by co-precipitation method have been evaluated. Since 
these particles are completely insoluble in water, they were incorporated into PLGA (Poly 
(lactic-co-glycolic acid) nanoparticles (PLGA-MNPs). The incorporation of magnetic 
nanoparticles inside PLGA-NPs has many advantages [13] 1) it improves the magnetic 
nanoparticles stability and bioavailability; 2) it allows their efficient dispersion in water; 3) it 
avoids their aggregation; 4) it hampers the Brownian relaxation by blocking magnetic 
nanoparticles inside the PLGA-MNPs solid core thus allowing Néel relaxation, also in the 
presence of larger particles. The results from the “in vitro” characterization can be 
immediately used for foreseeing the “in vivo” behaviour. The correlation between the field 
dependence of the longitudinal relaxation rate (R1obs), described by the so-called Nuclear 
Magnetic Resonance Dispersion (NMRD) profile, for nanoparticles and their heating power 
has been investigated. For iron oxide particles the inner sphere contribution to the water 
protons relaxation is negligible whereas the outer sphere term is the dominant one [14], 
essentially due to the diffusion of the water protons near the local variable magnetic field 
generated by the paramagnetic ion. Thus by analysing the dipolar interaction between proton 
spins and the magnetic moment it is possible to extrapolate important information about the 
magnetic nanoparticles, namely, their average radius r, their specific magnetization Ms, their 
anisotropy energy Ea, and their Néel relaxation time τN that determine the heating potential of 
the magnetic nanoparticles. Thus, supermagnetic nanoparticles are mostly used like negative 
contrast agent both in molecular and cellular imaging because of their negative enhancement 
effect on T2- and T2*-weighted images [15]. Taking advantage of this feature, to combine 
imaging and therapeutic allows and to create a theranostic agent, PLGA-MNPs have been 
loaded also with an anticancer hydrophobic drug currently used in the treatment of ovarian 
and breast cancer (Paclitaxel, PTX)(figure 1), in which, however, the drug release is triggered 
MFH [16]. 
 
Figure 1: A schematic representation of PLGA-MNPS-PTX and fields of application of this 
system 
RESULTS AND DISCUSSION  
Synthesis of MNPs and PLGA-MNPs  
The iron oxide magnetic nanoparticles (MNPs) used for the preparation of the PLGA 
nanocomposites (PLGA-MNPs) have been obtained by the co-precipitation in basic 
conditions from an iron (II/III) chlorides containing solution [17].  The size and morphology 
of the magnetic nanoparticles have been characterized by means of a TEM analysis (Figure 2 
A). For each sample the average size has been evaluated using ImageJ software and the 
average particle sizes are 9.7±2.8 (83%) and 18±1.7 (17%). As expected by nanoparticles 
obtained by co-precipitation a high dispersity and a large average diameter were observed 
[14].  
 
 
Figure 2: The TEM analysis of MNPs and PLGA-MNPs 
PLGA-MNPs were obtained by the o/w emulsion solvent extraction method [18]. The organic 
phase was prepared by dissolving PLGA RG 502H, MNPs and paclitaxel (PTX) in 
chloroform. The water phase was a poly (vinyl alcohol) (PVA) aqueous solution. PVA is the 
most commonly used emulsifier for the preparation of PLGA-MNPs because it yields 
particles that are relatively uniform, small sized, and easy to be re-dispersed in water [18]. 
The organic phase was added to the aqueous phase, and the resulting mixture was extensively 
sonicated. The nanospheres were obtained by slow organic solvent evaporation of the o/w 
emulsion. The iron encapsulation yield in PLGA-Fe-NPs is 68±9 %, determined by ICP-MS, 
while for PTX is 40±12%, determined by HPLC [14]. The average hydrodynamic diameters 
of PLGA-Fe-NPs have been obtained by dynamic light scattering (DLS) measurements, and 
they are 164±12 nm. In figure 2 the TEM image of PLGA-MNPs is reported. Figure 3 
displays the T1 magnetic field dependence (NMRD) of PLGA-MNPs [14]. 
 
 
Figure 3: NMRD profiles of PLGA-MNPs 
The shape of the curves is typical of the relaxation induced by superparamagnetic particles, 
i.e. the loading into the PLGA matrix seems to not affect the overall magnetic properties of 
the iron oxide particles. The water proton longitudinal relaxation arises from the dipolar 
interaction between the magnetic moments of water protons and the electron magnetic 
moment of the iron oxide particles and it is modulated by Néel relaxation (flip of the particle 
magnetic moment from different anisotropy directions) and water diffusion. At low magnetic 
fields, for particles with a diameter > 15 nm, the high crystal anisotropy maintains the particle 
magnetic moment locked onto the anisotropy axis. Since they can flip from one easy direction 
to another, the relaxation can occur through either Néel relaxation or water diffusion. On the 
contrary, at high magnetic fields, the Néel relaxation is not possible since the magnetic 
moment is locked onto the magnetic field direction and the modulation is due to water 
diffusion (τD). For very small particles, characterized by smaller anisotropy energy, the 
locking of the particle magnetization onto the anisotropy directions does not occur and Néel 
relaxation becomes negligible also at low magnetic fields [14].  
The NMRD profiles are fitted using the Roch's heuristic model [19], modified by Lascialfari 
et al[20] that has been developed for particle core diameter < 20nm.  Fitting equations have 
been written using Matlab and obtained data are reported in table [14].  
 
 rTEM [nm] rNMRD [nm] τD [ns] MS,NMRD [emu g-1] τN  [s rad-1] 
PLGA-C5 9.0 ± 0.9 13.2 ± 0.3 75.8 ± 3.9 62.1 ± 2.6 2.73 ± 0.48 x 10-7 
 
Table 1: The data obtained by fitting equations  
Assessment of magnetic hyperthermia properties 
   To assess hyperthermia capability of the PLGA-MNPs, they were exposed to a time varying 
magnetic field. The device to apply the time-varying magnetic field to magnetic nanoparticles 
is composed by a voltage generator EASYHEAT 8310 LI connected to a cylindrical inductor. 
The EASYHEAT 8310 LI supplies the inductor with a voltage up to 700 Vrms in a frequency 
range between 150 and 400 kHz, inductor designed to have a uniform magnetic field by 
means of finite element codes and optimization codes [21]. The copper inductor is a 
cylindrical solenoid with 7 turns, an internal diameter of 8 cm and a length of 15 cm. The 
sample is logged in Teflon container where a 5 ml glass vial is screwed to the cup of the 
container. The temperature is measured by means of an Optocom Fotemp-1H thermometer 
with a TS3/2 fiber optic. The fiber optic is inserted in the 5 ml glass vial by means of a hole in 
the center of the cup. The temperature is sampled with a time step of 1-s. The solutions were 
placed in an AC magnetic field of frequency (ν = 177 kHz, amplitude H0 = 18 kA/m; 
corresponding to a product H0 ν = 2.4x109 A m-1 s-1 ).The temperature increase generated by 
heat dissipation was recorded as a function of time of exposure to the AMF for 5min and 
30min (figure 4 A and B). 
 
Figura 4: Temperature increase as a function of time after exposition for 5min (A) and 30min 
(B) to AMF 
 
Typically, hyperthermal efficiency of a material is reported in terms of the specific absorption 
rate (SAR), reported in equation (4)  
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where C is the heat capacity of the suspension, m sample is the mass of the sample, miron  is 
the mass of iron, and Δt is the initial slope of the time-dependent heating curve, respectively 
[7]. The ΔT/Δt value was calculated by taking the initial slope of the temperature increase 
(50-150s) as in this time range the temperature increase was linear. The SAR value calculated 
for PLGA-MNPs is 34.57±2.25 W/g.  
 
“In vitro” Paclitaxel release triggered by MFH 
   Figure 5 shows the amount of PTX released by PLGA-MNPs after 30min or 5min of AMF 
exposure. The “In vitro” release of drug from treated nanoparticles was estimated in 
Phosphate Buffer Saline (PBS) at 6, 24 and 48h after AMF exposure. The heat produced 
during the MFH treatment is sufficient to destabilize PLGA-MNPs triggering their selective 
drug release that is significantly higher after 30 min of exposition to AMF than that measured 
on both control and on samples exposed to same magnetic field only for 5min [14]. 
PLGA-MNPs loaded with PTX at concentration of 2,3 μg/ml of drug were diluted in PBS 
(2ml) and transferred to dialysis bags  placed in PBS (50ml) with magnetic stirring at 110 
rpm/37 °C. At appropriate intervals, the buffer solution was replaced with fresh PBS, and the 
concentration of the released PTX in the removed PBS was determined by HPLC [14].  
 
Figure 5: Release of PTX after AMF exposition at different time intervals 
Magnetic Resonance Imaging of PLGA-MNPs on cell lines 
   PLGA-MNPs are evaluated as negative contrast agent for MRI and, eventually, as report in 
real time of in vivo distribution of both MNPs and the drug with which they are loaded.  
 
 
Figure 6: T2-weight image (A) and R2obs (B) of A549 cell line as function of concentration of 
iron  
A549, human alveolar basal epithelial adenocarcinoma cells, are incubated with PLGA-MNPs 
at different concentrations of iron for 24h. A T2-weighted MR image of an agar phantom 
containing A549 cells are acquired at 7T (Fig.6A). The graph of figure 6B shows the 
relaxation rates (R2obs) determined by MRI as a function of incubated iron concentration. By 
ICP-MS the iron concentration inside the cell due to aspecific endocytosis of PLGA-MNPs 
after 24h incubation was determined. The internalized iron was 6.4±2.4*10-9mol/mg of 
proteins that correspond to a concentration of 140±51 µM of iron inside the cellular pellet. 
Unfortunately, this concentration seems to be too low to obtain a detectable heating effect. 
However, Gordon et al. [22] suggested that internalised MNPs could be more effective at 
killing cancer cells because the cell membrane would act as an insulator enhancing the 
hyperthermic effect [4].  
With the advent of nanotechnology and the possibility of targeting MNPs to specific 
structures within the cell, the idea of selective destruction of these intracellular targets has 
become more attractive realized local heating and killing cancer cells without the need for a 
macroscopic temperature increase [4]. 
 
CONCLUSIONS  
Preliminary studies, herein reported, have shown that new nanosystems loaded with Fe-
NPs and Paclitaxel appear very promising for designing innovative “theranostic” applications. 
Furthermore the encapsulation of iron oxide inside the PLGA allows the characterization of 
insoluble MNPs and predicts hyperthermia efficiency, not hampered triggered release of drug 
from PLGA-NPs by MFH. Furthermore, with MRI the measurement of their concentration 
before the AFM treatment is possible. This permits to find the best time to perform the 
treatment thus increasing the probability of its success. 
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